Efficacy and Biomarker Data from BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
C. Zhou,Y. Wu,G. Chen,X. Liu,Y. Zhu,S. Lu,J. Feng,J. He,B. Han,J. Wang,G. Jiang,C. Hu,H. Zhang,G. Cheng,X. Song,Y. Lu,H. Pan,W. Zheng,A. Yin
DOI: https://doi.org/10.1016/j.ijrobp.2014.08.165
2014-01-01
Abstract:Bevacizumab plus platinum-doublet chemotherapy is effective as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC) in global populations. The efficacy benefit seen in mainly white patients is also consistently seen in Asian subpopulations. The BEYOND study was undertaken to confirm the efficacy and safety of first-line bevacizumab plus platinum-doublet chemotherapy in Chinese NSCLC patients. BEYOND was a randomized, double-blind, multicenter, placebo-controlled, phase 3 study of bevacizumab plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel in Chinese patients. The primary endpoint was progression-free survival (PFS) in the intent-to-treat (ITT) population; secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), exploratory biomarkers and safety. Patients were randomized 1:1 to receive CP (paclitaxel 175 mg/m2 i.v. and carboplatin AUC6 i.v. on day 1 of each 3-week cycle for up to 6 cycles), plus either placebo (Pl+CP) or bevacizumab (B+CP) 15 mg/kg i.v. on day 1 of each cycle, until progression, unacceptable toxicity, withdrawal of patient consent or death. The ITT population comprised 276 patients; B+CP, n=138, Pl+CP, n=138. The primary endpoint of PFS was prolonged with B+CP versus Pl+CP: HR 0.40 (95% CI 0.29-0.54; P<.0001); median PFS 9.2 versus 6.5 months. ORR was 54.4% with B+CP versus 26.3% with Pl+CP; DCR was 94.4% vs 88.7% with B+CP and Pl+CP, respectively. OS data will be presented. Median PFS in the EGFR mutation-positive subgroup was 12.4 months for B+CP and 7.9 months for Pl+CP. For those with EGFR wild-type disease, median PFS was 8.3 months for B+CP and 5.6 months for Pl+CP. Correlation between the EGFR mutation status data from tumor tissue samples and plasma samples will be presented. Safety results were consistent with those previously seen for a B+CP regimen. Updated safety results will be presented. The BEYOND study suggests that bevacizumab plus carboplatin/paclitaxel can be considered for first-line treatment of Chinese NSCLC patients. The analyses in EGFR mutation-positive disease confirm that EGFR mutations are prognostic for longer PFS, regardless of treatment; the increased benefit of B+CP was maintained in patients with EGFR mutation-positive and EGFR wild-type NSCLC.